107 related articles for article (PubMed ID: 7552510)
21. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
22. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
[TBL] [Abstract][Full Text] [Related]
23. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
24. Resistance testing debate: does it make the grade?
Simmons P
Res Initiat Treat Action; 1999 Oct; 5(4):9-12. PubMed ID: 11366943
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection--the Quattro Trial. Quattro Steering Committee.
AIDS; 1999 Nov; 13(16):2209-17. PubMed ID: 10563706
[TBL] [Abstract][Full Text] [Related]
26. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
28. [Laboratory diagnosis of HIV infection, viral tropism and resistance to antiretrovirals].
García F; Álvarez M; Bernal C; Chueca N; Guillot V
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):297-307. PubMed ID: 21345534
[TBL] [Abstract][Full Text] [Related]
29. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.
Schooley RT
AIDS; 1995 Dec; 9 Suppl 2():S15-S19. PubMed ID: 8775802
[TBL] [Abstract][Full Text] [Related]
30. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.
Wirden M; Soulie C; Valantin MA; Fourati S; Simon A; Lambert-Niclot S; Bonmarchand M; Clavel-Osorio C; Marcelin AG; Katlama C; Calvez V
J Antimicrob Chemother; 2011 Apr; 66(4):709-12. PubMed ID: 21393164
[TBL] [Abstract][Full Text] [Related]
31. Remune trials recruiting.
PI Perspect; 1996 Sep; (No 19):17. PubMed ID: 11363901
[TBL] [Abstract][Full Text] [Related]
32. [Antiretroviral treatments and their therapeutical trials].
Bazin C; Régnier B
Rev Prat; 1992 Jan; 42(2):148-53. PubMed ID: 1565997
[TBL] [Abstract][Full Text] [Related]
33. A fight to the death.
Short N
Nat Med; 1995 Feb; 1(2):122-4. PubMed ID: 7585006
[No Abstract] [Full Text] [Related]
34. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.
Coffin JM
Science; 1995 Jan; 267(5197):483-9. PubMed ID: 7824947
[TBL] [Abstract][Full Text] [Related]
35. Clinical trials in HIV infection: current problems and future directions.
Darbyshire J; Schoenfeld DA; Weller IV
AIDS; 1991; 5 Suppl 2():S167-73. PubMed ID: 1688258
[No Abstract] [Full Text] [Related]
36. Surrogate markers in AIDS research. Is there truth in numbers?
Levy JA
JAMA; 1996 Jul; 276(2):161-2. PubMed ID: 8656510
[No Abstract] [Full Text] [Related]
37. The role of viral dynamics in the pathogenesis of HIV disease and implications for antiviral therapy.
Havlir DV; Richman DD
Springer Semin Immunopathol; 1997; 18(3):267-83. PubMed ID: 9089949
[No Abstract] [Full Text] [Related]
38. Importance of surrogate markers in evaluation of antiviral therapy for HIV infection.
Deyton L
JAMA; 1996 Jul; 276(2):159-60. PubMed ID: 8656509
[No Abstract] [Full Text] [Related]
39. Pathogenicity and diversity of HIV and implications for clinical management: a review.
Saag MS; Hammer SM; Lange JM
J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 2():S2-10; discussion S10-1. PubMed ID: 7965648
[TBL] [Abstract][Full Text] [Related]
40. HIV viral dynamics.
Coffin JM
AIDS; 1996 Dec; 10 Suppl 3():S75-84. PubMed ID: 8970715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
